Evidence map›Paper›PMID 41201107›Full record

ArticleBiology open2025

Establishing an auxin-inducible GFP nanobody-based acute protein knockdown system to mimic hypomorphic mutations during early medaka embryogenesis.

Kaisa Pakari, Sevinç Jakab, Johanna Rasch, Encarnación Sánchez Salvador, Beate Wittbrodt, Christian Thiel, Joachim Wittbrodt, Thomas Thumberger

Abstract read
In one paragraph

Article in Biology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaisa PakariCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0001-8101-5252
Sevinç JakabCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0002-4604-6114
Johanna RaschCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.
Encarnación Sánchez SalvadorCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0001-8946-5637
Beate WittbrodtCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.
Christian ThielCenter for Child and Adolescent Medicine, Department Pediatrics I, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0001-6419-8747
Joachim WittbrodtCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0001-8550-7377
Thomas ThumbergerCOS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University, 69120 Heidelberg, Germany.ORCID 0000-0001-8485-457X

Funding

Deutsche Forschungsgemeinschaft TH1461/7-2Deutsche Forschungsgemeinschaft TH1992/1-2Deutsche Forschungsgemeinschaft WI1824/9-1European Research Council 810172European Research Council EXC 2082/1 Wittbrodt C3
6 · The paper itself

Abstract

Creating hypomorphic mutations is crucial to study gene function in vivo, especially when null mutations result in (embryonic) lethality. This applies to enzymes involved in glycosylation that, when mutated in human patients, cause the disease congenital disorders of glycosylation (CDG). In order to resemble patient condition, it would be ideal to acutely modulate the proteins in question to directly interfere with protein levels of such essential enzymes. These methods offer to establish pathogenic enzyme levels resembling net enzyme activity reported in patients suffering from CDG, with phosphomannomutase 2-CDG (PMM2-CDG) as the most common form. We established an auxin-inducible acute protein knockdown system for the use in the teleost fish medaka (Oryzias latipes) by combining an improved degron (AID2) technology with an mAID-nanobody targeting endogenously GFP-tagged Pmm2 protein. We generated a fishline expressing a functional Pmm2-GFP fusion protein, by single copy integration of GFP into the pmm2 locus. Upon induction, the degron system efficiently reduced Pmm2-GFP levels and enzyme activity, recapitulating the activity level of the hypomorphic mutations associated with PMM2-CDG in patients. This broadly applicable approach enables the investigation of CDG disease mechanisms during early embryonic development through reduction of protein abundance, mimicking hypomorphic mutations and thus substantially expanding the range of the genetic toolbox.

Indexed as

Embryonic DevelopmentGene Knockdown TechniquesGreen Fluorescent ProteinsIndoleacetic AcidsMutationOryziasAnimalsGlycosylationGreen Fluorescent ProteinsIndoleacetic AcidsCongenital disorders of glycosylationCRISPR/Cas9DegronEndogenous GFP-taggingMedakaPMM2-CDG

Identifiers

PMID41201107
PMCPMC12641487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.